Drug Trial Radar · NCT00422058
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
564
Actual
Start
Jan 10, 2007
Primary completion
Sep 13, 2007
Study completion Apr 30, 2009
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.
Conditions
- Metabolism and Nutrition Disorder
- Obesity
Interventions
liraglutideDrug
Injected s.c. (under the skin) once daily
orlistatDrug
120 mg capsule. Administered thrice daily
placeboDrug
Injected s.c. (under the skin) once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Body Weight at Week 20Time frame: Week 0, week 20
Locations
19 sites in 8 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Edegem, Belgium
Novo Nordisk Investigational Site
Prague, Czechia
Novo Nordisk Investigational Site
Prague, Czechia
Novo Nordisk Investigational Site
Århus C, Denmark
Novo Nordisk Investigational Site
Frederiksberg C, Denmark
Novo Nordisk Investigational Site
Hvidovre, Denmark
Novo Nordisk Investigational Site
Helsinki, Finland
Novo Nordisk Investigational Site
Kuopio, Finland
Novo Nordisk Investigational Site
Oulu, Finland
Novo Nordisk Investigational Site
Almere Stad, Netherlands
Novo Nordisk Investigational Site
Barcelona, Spain
Novo Nordisk Investigational Site
Madrid, Spain
Novo Nordisk Investigational Site
Madrid, Spain
Novo Nordisk Investigational Site
Pamplona, Spain
Novo Nordisk Investigational Site
Malmö, Sweden
Novo Nordisk Investigational Site
Stockholm, Sweden
Novo Nordisk Investigational Site
Glasgow, United Kingdom
Novo Nordisk Investigational Site
Luton, United Kingdom
Novo Nordisk Investigational Site
Norwich, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.